YU86101A - Inhibitori faktora viia - Google Patents

Inhibitori faktora viia

Info

Publication number
YU86101A
YU86101A YU86101A YUP86101A YU86101A YU 86101 A YU86101 A YU 86101A YU 86101 A YU86101 A YU 86101A YU P86101 A YUP86101 A YU P86101A YU 86101 A YU86101 A YU 86101A
Authority
YU
Yugoslavia
Prior art keywords
factor viia
compounds
formula
present
viia inhibitors
Prior art date
Application number
YU86101A
Other languages
English (en)
Inventor
Otmar Klingler
Gerhard Zoller
Elisabeth Defossa
Hans Matter
Pavel Safar
Original Assignee
Aventis Pharma Deutschland Gmbh.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland Gmbh. filed Critical Aventis Pharma Deutschland Gmbh.
Priority to MEP-577/08A priority Critical patent/MEP57708A/xx
Publication of YU86101A publication Critical patent/YU86101A/sh
Publication of RS50415B publication Critical patent/RS50415B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Ovaj pronalazak se odnosi na jedinjenja formule (I) u kojoj R1,R2, R92, R93, R94, R95, R96, R97, r, s i t imaju značenje kako je naznačeno u zahtevima. Jedinjenja formule (I) su vredna farmakološki aktivna jedinjenja. Ona pokazuju jak antitrombotski efekat i podesna su, na primer, za terapiju i profilaksu tromboembolnih obolenja ili restenoza. Ona su reversibilni inhibitori faktora enzima zgrušavanja krvi VIIa i mogu se generalno upotrebiti u uslovima u kojima je neželjena aktivnost faktora VIIa prisutna ili za lečenje ili prevenciju gde je namenjena inhibicija faktora VIIa. Pronalazak se dalje odnosi na postupke za dobijanje jedinjenja formule I, njihovo korišćenje, naročito kao aktivnih sastojaka kod farmaceutikala, i na farmaceutske preparate koji ih sadrže.
YUP-861/01A 1999-06-08 2000-05-27 Inhibitori faktora viia RS50415B (sr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MEP-577/08A MEP57708A (en) 1999-06-08 2000-05-27 Factor viia inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99111109A EP1059302A1 (en) 1999-06-08 1999-06-08 Factor VIIa inhibitors

Publications (2)

Publication Number Publication Date
YU86101A true YU86101A (sh) 2004-07-15
RS50415B RS50415B (sr) 2009-12-31

Family

ID=8238315

Country Status (32)

Country Link
US (1) US6500803B1 (sh)
EP (2) EP1059302A1 (sh)
JP (1) JP4546683B2 (sh)
KR (1) KR100979069B1 (sh)
CN (1) CN1359390B (sh)
AR (1) AR024292A1 (sh)
AT (1) ATE246707T1 (sh)
AU (1) AU774037B2 (sh)
BR (1) BR0011461A (sh)
CA (1) CA2376064C (sh)
CZ (1) CZ300365B6 (sh)
DE (1) DE60004363T2 (sh)
DK (1) DK1189929T3 (sh)
EE (1) EE04855B1 (sh)
ES (1) ES2202137T3 (sh)
HK (1) HK1047289B (sh)
HR (1) HRP20010912B1 (sh)
HU (1) HUP0201451A3 (sh)
IL (2) IL146731A0 (sh)
ME (1) MEP57708A (sh)
MX (1) MXPA01012568A (sh)
NO (1) NO328249B1 (sh)
NZ (1) NZ515966A (sh)
PL (1) PL202879B1 (sh)
PT (1) PT1189929E (sh)
RS (1) RS50415B (sh)
RU (1) RU2248359C2 (sh)
SI (1) SI1189929T1 (sh)
SK (1) SK286902B6 (sh)
TR (1) TR200103550T2 (sh)
WO (1) WO2000075172A2 (sh)
ZA (1) ZA200110053B (sh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1059302A1 (en) * 1999-06-08 2000-12-13 Aventis Pharma Deutschland GmbH Factor VIIa inhibitors
DE10005631A1 (de) * 2000-02-09 2001-08-23 Max Planck Gesellschaft Arginin-Mimetika als Faktor X¶a¶-Inhibitoren
GB0014134D0 (en) * 2000-06-10 2000-08-02 Astrazeneca Ab Combination therapy
JP4179878B2 (ja) * 2001-02-02 2008-11-12 中外製薬株式会社 ペプチド誘導体
GB0127615D0 (en) * 2001-07-09 2002-01-09 Aventis Pharm Prod Inc Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity
PL1658277T3 (pl) * 2003-08-18 2012-10-31 H Lundbeck As Sól bursztynianowa i malonianowa trans-4-((1R,3S)-6-chloro-3-fenyloindan-1-ylo)-1,2,2-tri-metylopiperazyny i zastosowanie jako lek
TWI376373B (en) 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
TWI453198B (zh) 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
US7456195B2 (en) * 2005-06-24 2008-11-25 Bristol-Myers Squibb Company Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants
US20080070987A1 (en) * 2006-05-12 2008-03-20 Francesc Yraola Font Meta-xylylenediamine vanadate salts
US11021514B2 (en) 2016-06-01 2021-06-01 Athira Pharma, Inc. Compounds
RS66218B1 (sr) 2019-07-01 2024-12-31 Tonix Pharma Ltd Anti-cd154 antitela i njihove upotrebe
WO2022150452A1 (en) 2021-01-06 2022-07-14 Seth Lederman Methods of inducing immune tolerance with modified anti-cd154 antibodies
WO2025248134A1 (en) 2024-05-31 2025-12-04 Tonix Pharma Limited Treatment methods comprising administration of modified cd154 antibodies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023236A (en) * 1988-04-07 1991-06-11 Corvas, Inc. Factor VII/VIIA active site inhibitors
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
DE4115468A1 (de) * 1991-05-11 1992-11-12 Behringwerke Ag Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel als antikoagulantien
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
EP1384725A3 (en) * 1994-04-26 2007-02-21 Aventis Pharmaceuticals Inc. Factor Xa inhibitors
PT892780E (pt) * 1996-02-22 2003-02-28 Bristol Myers Squibb Pharma Co Analogos de m-amidino fenilo como inibidores do factor xa
AR013084A1 (es) * 1997-06-19 2000-12-13 Astrazeneca Ab Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados
EP0987274A1 (en) * 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
EP1059302A1 (en) * 1999-06-08 2000-12-13 Aventis Pharma Deutschland GmbH Factor VIIa inhibitors

Also Published As

Publication number Publication date
TR200103550T2 (tr) 2002-05-21
EE04855B1 (et) 2007-06-15
DE60004363T2 (de) 2004-06-24
CN1359390B (zh) 2010-05-26
WO2000075172A3 (en) 2001-05-31
MEP57708A (en) 2011-05-10
SK286902B6 (sk) 2009-07-06
PL352200A1 (en) 2003-08-11
ES2202137T3 (es) 2004-04-01
EP1189929A2 (en) 2002-03-27
NO328249B1 (no) 2010-01-18
AU5397600A (en) 2000-12-28
KR20020020728A (ko) 2002-03-15
HK1047289B (zh) 2010-10-22
IL146731A (en) 2007-07-24
EE200100662A (et) 2003-04-15
BR0011461A (pt) 2002-03-19
NO20016005D0 (no) 2001-12-07
HUP0201451A2 (en) 2002-08-28
US6500803B1 (en) 2002-12-31
KR100979069B1 (ko) 2010-08-31
ZA200110053B (en) 2002-07-03
CN1359390A (zh) 2002-07-17
CA2376064A1 (en) 2000-12-14
RS50415B (sr) 2009-12-31
AU774037B2 (en) 2004-06-17
RU2248359C2 (ru) 2005-03-20
DK1189929T3 (da) 2003-11-24
NZ515966A (en) 2003-09-26
SI1189929T1 (en) 2004-02-29
HRP20010912B1 (en) 2010-10-31
HUP0201451A3 (en) 2003-08-28
DE60004363D1 (de) 2003-09-11
HRP20010912A2 (en) 2003-04-30
MXPA01012568A (es) 2002-04-10
JP4546683B2 (ja) 2010-09-15
NO20016005L (no) 2002-02-06
PT1189929E (pt) 2003-12-31
EP1189929B1 (en) 2003-08-06
EP1059302A1 (en) 2000-12-13
IL146731A0 (en) 2002-07-25
SK17592001A3 (sk) 2002-05-09
AR024292A1 (es) 2002-09-25
HK1047289A1 (zh) 2003-02-14
PL202879B1 (pl) 2009-07-31
JP2003502294A (ja) 2003-01-21
CZ300365B6 (cs) 2009-04-29
CA2376064C (en) 2011-04-26
CZ20014357A3 (cs) 2002-03-13
WO2000075172A2 (en) 2000-12-14
ATE246707T1 (de) 2003-08-15

Similar Documents

Publication Publication Date Title
MEP43008A (en) Indole-2-carboxamides as factor xa inhibitors
YU86101A (sh) Inhibitori faktora viia
DK0559743T3 (da) Nye hydroxamsyre- og N-hydroxyurinstofderivater og deres anvendelse
ATE293617T1 (de) Oxybenzamidderivate als faktor-xa-inhibitoren
IS7925A (is) Hýdroxýetýlamínafleiður til að meðhöndla Alzheimers-sjúkdóm
YU89202A (sh) Faktor viia inhibitorni derivati (tio)uree, njihovo dobijanje i upotreba
EE03435B1 (et) Maatriksmetalloproteaasi inhibeeriva aktiivsusega ühendid, nende valmistamismeetodid ja kasutamine, vaheprodukt ja kompositsioon
DE60329316D1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
HUP0100558A2 (hu) S-Oxid- és S,S-dioxid-tetrahidrotiopirán-fenil-oxazolidinon-származékok, e vegyületek alkalmazása gyógyászati készítmények előállítására, valamint eljárás e vegyületek gátló hatásának meghatározására humán-monoamin-oxidázzal szemben
ATE388951T1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
MY107740A (en) Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
BRPI0208811B8 (pt) derivados de pirazol, seu uso e processo de preparação, bem como composição farmacêutica compreendendo os mesmos
TR200101903T2 (tr) Yeni malonik asit türevleri, bunların preparasyon işlemleri.
TW200510393A (en) New indole derivatives as factor Xa inhibitors
BR0011745A (pt) Inibidores de aspartil protease
HUP9700005A2 (hu) 2-Ureido-benzamid-származékok és ilyeneket hatóanyagként tartalmazó gyógyszerkészítmények
DE60214569D1 (de) Harnstoffverbindungen mit antiproteolytischer wirkung
YU29702A (sh) N-gvanidinoalkilamidi, njihovo dobijanje, njihova primena i farmaceutski preparati koji ih obuhvataju
NO995594D0 (no) Nye substituerte heterocykliske forbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem
TW200504027A (en) Imidazole-derivatives as factor Xa inhibitors
TNSN05296A1 (en) AZAINDOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
TW200716620A (en) Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide-derivatives as factor Xa inhibitors
DE60321700D1 (de) Pyrazolderivate und deren verwendung als therapeutische mittel für durch hiv vermittelte krankheiten
HUP0204144A2 (en) N-(1-phenylethyl)-5-phenyl-imidazole-2-amine compounds, their compositions and uses
JO2467B1 (en) New indole derivatives as an inhibitor of Xa